Jan 15, 2021
  • Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic idiopathic urticaria (CIU) in patients with an inadequate response to H1 anthistamines1
  • Currently there are limited approved therapies for patients with CIU, also known as chronic spontaneous urticaria (CSU)
  • Breakthrough Therapy designation suggests ligelizumab has the potential to provide a substantial benefit over existing available treatments
  • US regulatory filing in CIU is anticipated in 2022

East Hanover, January 14, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has granted ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU), in patients who have an inadequate response to H1 antihistamine treatment.

CIU is an unpredictable and severe disease of the skin, affecting 0.5-1% of the global population at any time2. It is characterized by the development of itchy, painful wheals (hives), swelling (angioedema), or both, lasting for at least 6 weeks and occurring with no known cause3. CIU can be challenging or frustrating for patients due to the severity and unpredictable nature4. It most commonly persists for 1-5 years, but in some cases, even longer2.

“Chronic idiopathic urticaria can be a frustrating and debilitating condition for patients because the symptoms can disrupt daily life,” said Victor Bultó, President, Novartis Pharmaceuticals Corporation. “The granting of Breakthrough Therapy designation is welcome news for those who suffer from the disease because there are not many treatment options available to them. We look forward to working closely with the FDA to bring a potential new treatment option to those that need it most.”

According to FDA guidelines, treatments that receive Breakthrough Therapy designation must target a serious or life-threatening disease and demonstrate a potential substantial improvement over existing therapies on one or more significant clinical endpoints5.

About ligelizumab (QGE031)

Ligelizumab is a next-generation monoclonal anti-immunoglobulin E (IgE) antibody. Ligelizumab is thought to work by blocking the IgE/FcεRI pathway, a key driver of the inflammatory process in CIU6,7. In a Phase IIb dose-finding trial, more patients experienced complete resolution of wheals (hives) with ligelizumab compared with Xolair (omalizumab)8. No safety concerns were found with ligelizumab compared with omalizumab or placebo8. Ligelizumab compared with omalizumab is currently being investigated in ongoing Phase III clinical trial programs including PEARL 1 and PEARL 2 (NCT03580369 and NCT03580356)9,10. The clinical trials have recruited more than 2,000 patients globally across 48 countries and results are expected in the second half of 20219,10.

About Novartis in CIU

Novartis is curious about the science beneath the skin and dedicated to reimagining the care of patients with diseases that can severely limit quality of life such as CIU, psoriasis, acne and atopic dermatitis. Advancing ligelizumab further strengthens the immuno-dermatology pipeline of Novartis. In the US, Novartis and Genentech, a member of the Roche Group, work together to develop and co-promote Xolair. Outside the US, Novartis markets Xolair and records all sales and related costs. Xolair is indicated as an add-on therapy for the treatment of CIU. Novartis is also testing remibrutinib (LOU064), a Bruton’s tyrosine kinase (BTK) inhibitor that is being tested in Phase II clinical studies for CIU11.

About Novartis

Located in East Hanover, NJ Novartis Pharmaceuticals Corporation – an affiliate of Novartis – is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis employs more than 15,000 people in the United States. For more information, please visit https://www.novartis.us.

Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews and @NovartisUS at https://twitter.com/NovartisUS.

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact [email protected].

# # #

Novartis Media Relations
E-mail: [email protected]

Eric Althoff Jamie Bennett
Head, US Corp & Country External Comms, Director, US Media Relations
Global Media & Corp Communications +1 862 217 3976
+1 646 438 4335 [email protected]
[email protected]  

Novartis Investor Relations
E-mail: [email protected]

Sloan Simpson +1 862 778 5052

References

  1. US Food and Drug Administration (FDA). CDER Breakthrough Therapy designation approvals as of December 31, 2019. Accessed December 2020. https://www.fda.gov/media/95302/download
  2. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria: a GA2LEN task force report. Allergy. 2011;66(3):317-330.
  3. Vestergaard C, Deleuran M. Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. Ther Adv Chronic Dis. 2015;6(6):304-313.
  4. Ferrer, M., Bartra, J., Giménez‐Arnau, A., Jauregui, I., Labrador‐Horrillo, M., Ortiz de Frutos, J., Silvestre, J. F., Sastre, J., Velasco, M., Valero, A., Clinical & Experimental Allergy, 2015 ( 45) 731– 743.
  5. US Food and Drug Administration (FDA). Frequently asked questions: breakthrough therapies. Accessed December 2020. https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/frequently-asked-questions-breakthrough-therapies
  6. Puxeddu I, Pratesi F, Ribatti D, Migliorini P. Mediators of inflammation and angiogenesis in chronic spontaneous urticaria: are they potential biomarkers of the disease? Mediators Inflamm. 2017;4123694.
  7. Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165.
  8. Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321-1332.
  9. US National Library of Medicine (NIH). ClinicalTrials.gov. A Phase III study of the efficacy and safety of ligelizumab in the treatment of CSU in adolescents and adults inadequately controlled with H1-histamines. Posted July 9, 2018. Updated December 8, 2020. Accessed December 2020. https://clinicaltrials.gov/ct2/show/NCT03580369. ID: NCT03580369.
  10. US National Library of Medicine (NIH). ClinicalTrials.gov. A Phase III study of the efficacy and safety of ligelizumab in the treatment of CSU in adolescents and adults inadequately controlled with H1-histamines. Posted July 9, 2018. Updated December 9, 2020. Accessed December 2020. https://clinicaltrials.gov/ct2/show/NCT03580356. ID: NCT03580356.
  11. US National Library of Medicine (NIH). ClinicalTrials.gov. NCT03926611. Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines. Posted April 24, 2019. Updated December 9, 2020. Accessed January 2021. https://clinicaltrials.gov/ct2/show/NCT03926611. ID: NCT03926611.